Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells

Prostate

Volumn 74, Issue 2, 2014, Pages 201-209

  Liu, Chengfei ^a   Zhu, Yezi ^a,b   Lou, Wei ^a   Cui, Yuanyuan ^a   Evans, Christopher P ^a,c   Gao, Allen C ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

enzalutamide; Interleukin 6; prostate cancer; Stat3

Indexed keywords

ENZALUTAMIDE; INTERLEUKIN 6; MYC PROTEIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; SMALL INTERFERING RNA; STAT3 PROTEIN; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL GROWTH ASSAY; CELL STRAIN LNCAP; CLONOGENIC ASSAY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ENZALUTAMIDE; INTERLEUKIN-6; PROSTATE CANCER; STAT3;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; INTERLEUKIN-6; MALE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TYRPHOSTINS;

EID: 84891160894     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22741     Document Type: Article

References (29)

1. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS,. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367 (13): 1187-1197.
2. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL,. Antitumour activity of MDV 3100 in castration-resistant prostate cancer: A phase1-2 study. Lancet 2010; 375 (9724): 1437-1446.
3. Ben Jemaa A, Sallami S, Ramarli D, Colombatti M, Oueslati R,. The proinflammatory cytokine, IL-6, and its interference with bFGF signaling and PSMA in prostate cancer cells. Inflammation 2013; 36 (3): 643-650.
4. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L,. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334 (Pt 2): 297-314.
5. Duffy SA, Teknos T, Taylor JM, Fowler KE, Islam M, Wolf GT, McLean S, Ghanem TA, Terrell JE,. Health behaviors predict higher interleukin-6 levels among patients newly diagnosed with head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2013; 22 (3): 374-381.
6. Hao W, Zhu Y, Zhou H,. Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer. Med Oncol 2013; 30 (1): 333.
7. Yanaihara N, Anglesio MS, Ochiai K, Hirata Y, Saito M, Nagata C, Iida Y, Takakura S, Yamada K, Tanaka T, Okamoto A,. Cytokine gene expression signature in ovarian clear cell carcinoma. Int J Oncol 2012; 41 (3): 1094-1100.
8. Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD,. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011; 17 (8): 2538-2548.
9. Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, Buring J, Chanock SJ, Clavel-Chapelon F, Feigelson HS, Gaziano JM, Giovannucci E, Gonzalez C, Haiman CA, Hallmans G, Hankinson SE, Hayes RB, Henderson BE, Hoover RN, Hunter DJ, Khaw KT, Kolonel LN, Kraft P, Ma J, Le Marchand L, Lund E, Peeters PH, Stampfer M, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D, Tumino R, Riboli E, Virtamo J, Weinstein SJ, Yeager M, Ziegler RG, Cox DG,. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: Results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 2010; 31 (3): 455-461.
10. Iacopino F, Pinto F, Bertaccini A, Calarco A, Proietti G, Totaro A, Martorana G, Bassi P, Sica G,. Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy. Oncol Rep 2012; 28 (1): 370-374.
11. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM,. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001; 58 (6): 1008-1015.
12. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M,. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6 (7): 2702-2706.
13. Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ, Evans CP, Gao AC,. Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 2009; 15 (15): 4815-4822.
14. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC,. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003; 9 (1): 370-376.
15. Bromberg J, Wang TC,. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009; 15 (2): 79-80.
16. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC,. Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. Prostate 2000; 42 (3): 239-242.
17. DeMiguel F, Lee SO, Lou W, Xiao X, Pflug BR, Nelson JB, Gao AC,. Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate 2002; 52 (2): 123-129.
18. Liu C, Nadiminty N, Tummala R, Chun JY, Lou W, Zhu Y, Sun M, Evans CP, Zhou Q, Gao AC,. Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer 2011; 2 (2): 151-159.
19. Feng S, Tang Q, Sun M, Chun JY, Evans CP, Gao AC,. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther 2009; 8 (3): 665-671.
20. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC,. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 2007; 67 (7): 764-773.
21. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye M, McEachern K, Chen H, Morosini D, Bell K, Alimzhanov M, Ioannidis S, McCoon P, Cao ZA, Yu H, Jove R, Zinda M,. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16 (6): 487-497.
22. Yu H, Kortylewski M, Pardoll D,. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7 (1): 41-51.
23. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Nevalainen MT,. Stat3 promotes metastatic progression of prostate cancer. Am J Pathol 2008; 172 (6): 1717-1728.
24. Payton S,. Prostate cancer: MDV3100 has antitumor activity in castration-resistant disease. Nat Rev Urol 2010; 7 (6): 300.
25. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL,. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324 (5928): 787-790.
26. Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, Hirsch B, Beckman KB, Silverstein KA, Dehm SM,. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 2012; 31 (45): 4759-4767.
27. Hodge DR, Hurt EM, Farrar WL,. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41 (16): 2502-2512.
28. Grivennikov S, Karin M,. Autocrine IL-6 signaling: A key event in tumorigenesis ? Cancer Cell 2008; 13 (1): 7-9.
29. Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S, Chang C,. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis 2013; 4: e764.